Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial.

Masato YonedaYasushi HondaYuji OgawaTakaomi KessokuTakashi KobayashiKento ImajoAnna OzakiAsako NogamiMasataka TaguriTakeharu YamanakaHiroyuki KirikoshiTomoyuki IwasakiTakeo KurihashiSatoru SaitoHirokazu Takahashi

Published in: BMJ open diabetes research & care (2021)

jRCTs031180159.

Keyphrases

open label
end stage renal disease
chronic kidney disease
newly diagnosed
clinical trial
study protocol
prognostic factors
peritoneal dialysis
randomized controlled trial
squamous cell carcinoma
liver fibrosis
placebo controlled